Europe Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies); and Country
Market Introduction
Late-stage renal disease, also defined as end-stage kidney disease, occurs with the gradual loss of kidney function at an advanced state. In end-stage renal disease, kidneys can no longer filter wastes, and excess fluids from blood and wastes can build up in the body.
Market Overview and Dynamics
The Europe late-stage chronic kidney disease drugs market is expected to reach US$ 2,919.58 million by 2027 from US$ 1,256.98 million in 2019; it is estimated to grow at a CAGR of 11.3% from 2020 to 2027. The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policies for the late-stage chronic kidney disease treatments are among the prime factors furling the market growth in this region. However, delay in the diagnosis of chronic kidney disease hampers the growth of the market.
Based on product type, Europe late-stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the largest share of the market in 2019, and it is expected to register the highest CAGR in the market during 2020–2027.
The Europe late-stage chronic kidney disease drugs market, by indication, is segmented into late-stage chronic kidney disease induced hyperparathyroidism, late-stage chronic kidney disease induced hyperphosphatemia, and late-stage chronic kidney disease induced hyperkalemia. The late-stage chronic kidney disease induced hyperparathyroidism segment held the largest share of the market in 2019, and it is estimated to register the highest CAGR in during the forecast period.
On the basis of distribution channel, the Europe late-stage chronic kidney disease drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest share of the market in 2019; however, the market for online pharmacies is expected to grow at the highest CAGR from 2020 to 2027.
Major Sources and Companies Listed
Some of the primary and secondary sources associated with this report on the Europelate stage chronic kidney disease drugs market are World Health Organization (WHO); Centers for Disease Control and Prevention (CDC); and National Institutes of Health (NIH).
Reasons to buy the report
· Determine prospective investment areas based on a detailed trend analysis of the Europelate stage chronic kidney disease drugs market over the next years.
· Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
· Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
· Identify the major channels driving theEuropelate stage chronic kidney disease drugs market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
· Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Europelate stage chronic kidney disease drugs market.
EUROPE LATE STAGE CHRONIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION
By Product Type
· Calcimimetics
· Vitamin D
· Sterols
· Potassium Binders
· Calcium-Based Phosphate Binders
· Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
· Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
· Late Stage Chronic Kidney Disease Induced Hyperkalaemia
· Hospital Pharmacies
· Online Pharmacies
· Retail Pharmacies
By Country
· UK
· Germany
· France
· Italy
· Spain
· Rest of Europe
Company Profiles
· AbbVie Inc
· Amgen
· AstraZeneca
· Sanofi
· Kyowa Kirin Co., Ltd
· Takeda Pharmaceutical Company Limited
· Astellas Pharma Inc
· Bayer AG
· Vifor Pharma Management Ltd
· Akebia Therapeutics, Inc
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Late Stage Chronic Kidney Disease Drugs Market – By Product Type
1.3.2 Europe Late Stage Chronic Kidney Disease Drugs Market – By Indication
1.3.3 Europe Late Stage Chronic Kidney Disease Drugs Market – By Distribution Channel
1.3.4 Europe Late Stage Chronic Kidney Disease Drugs Market – By Country
2. Late Stage Chronic Kidney Disease Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Late Stage Chronic Kidney Disease Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe – PEST Analysis
4.3 Expert Opinion
5. Late Stage Chronic Kidney Disease Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Diseases Leading to Chronic Kidney Diseases
5.1.2 Favourable Reimbursement Policy for the Late Stage Chronic Kidney Disease Drugs
5.2 Market Restraints
5.2.1 Delay in the Diagnosis of Chronic Kidney Disease
5.3 Market Opportunities
5.3.1 Introduction of New Late Stage Chronic Kidney Disease Drugs
5.4 Future Trends
5.4.1 Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development
5.5 Impact Analysis
6. Late Stage Chronic Kidney Disease Drugs Market – Europe Analysis
6.1 Europe Late Stage Chronic Kidney Disease Drugs Market Revenue Forecast and Analysis
7. Late Stage Chronic Kidney Disease Drugs Market Analysis – By Product Type
7.1 Overview
7.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
7.3 Calcimimetics
7.3.1 Overview
7.3.2 Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Vitamin D
7.4.1 Overview
7.4.2 Vitamin D: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Potassium Binders
7.5.1 Overview
7.5.2 Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Calcium-Based Phosphate Binders
7.6.1 Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.7 Others
7.7.1 Others: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8. Late Stage Chronic Kidney Disease Drugs Market Analysis by Indication
8.1 Overview
8.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
8.3 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
8.3.1 Overview
8.3.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
8.4.1 Overview
8.4.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Late Stage Chronic Kidney Disease Induced Hyperkalemia
8.5.1 Overview
8.5.2 Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9. Late Stage Chronic Kidney Disease Drugs Market Analysis by Distribution Channel
9.1 Overview
9.2 Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Online Pharmacies
9.4.1 Overview
9.4.2 Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Retail Pharmacies
9.5.1 Overview
9.5.2 Retail Pharmacies Segment: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
10. Late Stage Chronic Kidney Disease Drugs Market Analysis and Forecasts To 2027 – Europe Analysis
10.1 Europe: Late Stage Chronic Kidney Disease Drugs Market
10.1.1 Overview
10.1.2 Europe: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.3 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.4 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.5 Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.6 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
10.1.7 Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.7.3 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.7.4 Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.8 France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.8.3 France: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.8.4 France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.9 UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.1 UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.2 UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.9.3 UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.9.4 UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.10 Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.1 Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.2 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.10.3 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.10.4 Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.11 Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.1 Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.2 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.11.3 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.11.4 Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on Europe Late Stage Chronic Kidney Disease Drugs Market
11.1 Europe: Impact Assessment of COVID-19 Pandemic
12. Company Profiles
12.1 AbbVie Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Amgen
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 AstraZeneca
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sanofi
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Kyowa Kirin Co., Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Takeda Pharmaceutical Company Limited
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Astellas Pharma Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Bayer AG
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Vifor Pharma Management Ltd.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Akebia Therapeutics, Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 Glossary of Terms
LIST OF TABLES
Table 1. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 2. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 3. Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 4. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 5. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 6. Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 7. France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 8. France: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 9. France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 10. UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 11. UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 12. UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 14. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 15. Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 16. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 17. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 18. Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 19. Glossary of Terms, Late Stage Chronic Kidney Disease Drugs Market
LIST OF FIGURES
Figure 1. Late Stage Chronic Kidney Disease Drugs Market Segmentation
Figure 2. Late Stage Chronic Kidney Disease Drugs Market – By Country
Figure 3. Europe Late Stage Chronic Kidney Disease Drugs Market Overview
Figure 4. Calcimimetics Segment Held Largest Share of Late Stage Chronic Kidney Disease Drugs Market
Figure 5. Europe Late Stage Chronic Kidney Disease Drugs Market- Leading Country Markets (US$ Million)
Figure 6. Europe PEST Analysis
Figure 7. Late Stage Chronic Kidney Disease Drugs Market Impact Analysis of Driver and Restraints
Figure 8. Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue Forecast and Analysis – 2019- 2027
Figure 9. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
Figure 10. Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. Vitamin D: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 13. Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. Others: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 15. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
Figure 16. Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 19. Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027 (%)
Figure 20. Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. Retail Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 23. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 24. Europe: Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 25. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
Figure 26. Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 27. France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 28. UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 29. Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. Impact of COVID-19 Pandemic on Late Stage Chronic Kidney Disease Drugs Market in European Countries
- AbbVie Inc
- Amgen
- AstraZeneca
- Sanofi
- Kyowa Kirin Co., Ltd
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc
- Bayer AG
- Vifor Pharma Management Ltd
- Akebia Therapeutics, Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe Last Stage Chronic Kidney Disease Drugs market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the EuropeLast Stage Chronic Kidney Disease Drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.